Neuland Laboratories Limited
11th floor (5th level), Phoenix IVY Building,
Plot No.573A-III, Road No.82, Jubilee Hills,
Hyderabad-500033, Telangana, India.

CONTACT
040 6761 1600 / 6761 1700
neuland@neulandlabs.com
neulandlabs.com

neuland

August 5, 2026

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai – 400 001

Scrip Code: 524558

The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai – 400 001

Scrip Code: NEULANDLAB; Series: EQ

Dear Sir/Madam,

Sub: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing Press Release on the Financial Results of the Company for the quarter ended June 30, 2026.

The Press Release is also being uploaded on the website of the Company at www.neulandlabs.com

This is for your information and records.

Yours sincerely,
For **Neuland Laboratories Limited**
SARADA BHAMIDIPATI
Digitally signed by SARADA BHAMIDIPATI
Date: 2026.08.05 16:12:14 +05'30'
Sarada Bhamidipati
Company Secretary

Encl: As above

Neuland Q1FY27 Total income at Rs.650.1 crore; EBITDA at Rs.231.1 crore

Hyderabad, India, August 5, 2026 – Neuland Laboratories Limited (NLL) (NSE: NEULANDLAB; BSE:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in around 80 countries, today announced financial results for the quarter ended June 30, 2026.

Commenting on the performance Mr. Saharsh Davuluri, Chief Executive Officer and Managing Director, Neuland Laboratories added *"Q1 FY27 was broadly in line with our expectations with encouraging performance from both CMS & GDS businesses and represents a good start to the year. While Commercial Products contributed to most of the revenue, we are seeing exciting developments in terms of the pipeline projects. The depth of customer conversations today is significantly stronger, and we are increasingly engaging on broader capability-led discussions rather than individual projects alone. Internally our focus now is on ensuring that we deliver consistently, build customer confidence and establish the foundation for long-term partnerships. Even as we have invested significantly over the last three years and all our significant Capex projects are proceeding according to plan, I believe the intensity of our investments will further increase based on the opportunities that available to us."*

Financial Summary

Rs. crore

Particulars	Q1FY27	Q1FY26	YoY (%)	Q4FY26	QoQ (%)
Total Income	650.1	300.6	116.3%	788.7	-17.6%
EBITDA	231.1	42.1	448.2%	319.4	-27.6%
EBITDA Margin	*35.5%*	*14.0%*	*2150 bps*	*40.5%*	*-500 bps*
Profit Before Tax	197.5	17.4	1036.7%	287.0	-31.2%
PBT Margin	*30.4%*	*5.8%*	2460 bps	*36.4%*	-601 bps
Profit After Tax	147.4	13.7	975.0%	212.5	-30.6%
PAT Margin	*22.7%*	*4.6%*	1811 bps	*26.9%*	-423 bps
EPS (Rs.)	114.9	10.7	975.0%	165.6	-30.6%

Q1 FY27 Earnings Call

The company will conduct a one-hour Earnings call at **17:30 hrs. IST** on **Wednesday, August 5, 2026** where the management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please register on the link below:

Diamond Pass Registration Link

Webcast Link

Please note that the transcript of the conference call will be uploaded on the company website in due course.

About Neuland Laboratories Limited

For over 4 decades, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 100 APIs and has filed around 1010+ Regulatory filings across the US (75 active US DMFs), the European Union (EU) and other geographies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID & GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit www.NeulandLabs.com.

If you have any questions or require further information, please feel free to contact

IR Department at Neuland
Tel: +91 40 6761 1600
Email: ir@neulandlabs.com
Runjun Jain / Minakshi Machutre
EY IR
Email: Runjhun.Jain1@in.ey.com / *Minakshi.machutre@in.ey.com*